Omacetaxine (HHT*) CML Trials
CML Clinical Trials - Open for Enrollment
THERE ARE TWO CLINICAL TRIALS OF OMACETAXINE BEING CONDUCTED IN PATIENTS WITH CML:
|
STUDY 202
A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine* (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation
*now known as omacetaxine
If you have a CML patient with the T315I mutation please click here for more information on the study.
If you would like to find a hospital near you that is participating in this study, please click here. |
STUDY 203
A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine* (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) who have Failed or are intolerant to Tyrosine Kinase Inhibitor Therapy
*now known as omacetaxine
If you have a CML patient who has failed TKI therapy please click here for more information on the study.
If you would like to find a hospital near you that is participating in this study, please click here. |
